Sarepta Therapeutics, Inc.SRPTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

26 analysts·High coverage

38%

Rating Distribution

Strong Buy

00%

Buy

1038%

Hold

1246%

Sell

415%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case

$12.00

-41%

Consensus

$20.38

+0%

Bull Case

$32.00

+57%

Price Range26 analysts

Low

Consensus

High

$12.00

$32.00

Current Target

Current Price

$20.34

Upside to Target

$0.04

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$1.93(12 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-3.14%

EPS+34.75%

FY2028

Rev-6.44%

EPS-48.13%

FY2029

Rev+2.56%

EPS+33.71%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+321.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Robert W. Baird

Sarepta price target raised to $22 from $15 at Baird

Target:$22.00

-3.5%from $22.80

Dec 9, 2025Wedbush

Wedbush bullish on Sarepta, initiates with an Outperform

Target:$32.00

+46.4%from $21.86

Nov 25, 2025Bernstein

Sarepta price target raised to $20 from $18 at Bernstein

Target:$20.00

+5.8%from $18.91

Nov 5, 2025Barclays

Sarepta price target lowered to $20 from $22 at Barclays

Target:$20.00

+23.5%from $16.20

Nov 5, 2025Mizuho Securities

Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform

Target:$26.00

+60.5%from $16.20

Nov 4, 2025Robert W. Baird

Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird

Target:$15.00

-38.7%from $24.45

Oct 30, 2025Piper Sandler

Sarepta price target raised to $16 from $15 at Piper Sandler

Target:$16.00

-31.8%from $23.45

Sep 9, 2025Leerink Partners

Sarepta price target raised to $15 from $12 at Leerink

Target:$15.00

-14.6%from $17.57

Aug 21, 2025Barclays

Sarepta debt refinancing eases liquidity concerns, says Barclays

Target:$22.00

+9.7%from $20.06

Aug 15, 2025Deutsche Bank

Sarepta price target raised to $12 from $6 at Deutsche Bank

Target:$12.00

-40.9%from $20.30

Jul 22, 2025Barclays

Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight

Target:$18.00

+35.1%from $13.32

Jul 21, 2025BMO Capital

BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

Target:$50.00

+255.2%from $14.07

Jul 19, 2025Leerink Partners

Sarepta downgraded to Market Perform from Outperform at Leerink

Target:$10.00

-29.0%from $14.07

Jun 25, 2025H.C. Wainwright

Sarepta has little value if Elevidys withdrawn, says H.C. Wainwright

Target:$10.00

-42.7%from $17.46

Jun 17, 2025Wells Fargo

Sarepta price target lowered to $75 from $100 at Wells Fargo

Target:$75.00

+247.9%from $21.56

Jun 16, 2025Cantor Fitzgerald

Sarepta downgraded to Neutral from Overweight at Cantor Fitzgerald

Target:$20.00

-4.5%from $20.94

Jun 15, 2025BMO Capital

Sarepta downgraded to Market Perform from Outperform at BMO Capital

Target:$70.00

+93.5%from $36.18

Apr 21, 2025Piper Sandler

Sarepta price target lowered to $110 from $182 at Piper Sandler

Target:$110.00

+99.2%from $55.23

Nov 27, 2024Piper Sandler

Sarepta Therapeutics (SRPT) PT Lowered to $182 at Piper Sandler

Target:$182.00

+33.0%from $136.87

Nov 27, 2024Needham

Sarepta Therapeutics (SRPT) PT Lowered to $202 at Needham

Target:$202.00

+47.6%from $136.87

Nov 7, 2024Robert W. Baird

Sarepta Therapeutics (SRPT) PT Lowered to $193 at Baird

Target:$193.00

+54.5%from $124.95

Nov 7, 2024Cantor Fitzgerald

Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) to Overweight

Target:$167.00

+33.7%from $124.95

Oct 21, 2024Jefferies

Jefferies Starts Sarepta Therapeutics (SRPT) at Buy

Target:$165.00

+29.8%from $127.08

Aug 8, 2024Evercore ISI

Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform

Target:$179.00

+31.2%from $136.40

Aug 8, 2024Piper Sandler

Sarepta price target lowered to $200 from $205 at Piper Sandler

Target:$200.00

+42.8%from $140.06

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance